Treatment of moderate to severe vasomotor symptoms (VMS).
LYNKUET — BAYER HLTHCARE, approved 2025-10-24 (NDA219469).
112 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.